Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder affecting approximately 1% of individuals aged 60 and above. The disease is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to motor and non-motor symptoms.
The hallmark pathological feature of PD is the presence of Lewy bodies, abnormal aggregates of the protein alpha-synuclein, in the remaining dopaminergic neurons. The exact mechanism of neuronal death is still under investigation, but it is believed that oxidative stress, mitochondrial dysfunction, and protein misfolding all play a role. The loss of dopamine in the basal ganglia results in an imbalance of excitatory and inhibitory signals, leading to the characteristic motor symptoms of PD.
PD presents with a combination of motor symptoms (tremor, bradykinesia, rigidity, and postural instability) and non-motor symptoms (depression, cognitive impairment, and autonomic dysfunction). Diagnosis is primarily clinical, based on the presence of motor symptoms and response to dopaminergic medications. Neuroimaging can be useful in uncertain cases, but is not routinely recommended.
Management of PD is multidimensional, involving pharmacological and non-pharmacological approaches. Pharmacological treatment is centered around augmenting dopamine levels in the brain, primarily through the use of levodopa. Non-pharmacological strategies include physical therapy, occupational therapy, and speech therapy. Deep brain stimulation is an option for patients with advanced disease and severe motor fluctuations.
Understanding the pathophysiology and management of PD is crucial for healthcare professionals to provide optimal care for these patients. While there is currently no cure for PD, ongoing research promises the potential for new therapeutic strategies in the future.
1.
Scholastic performance is a key concern for young cancer patients, study finds
2.
With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.
3.
Vistagen's Anxiety Disorder Drug Misses Main Goal in Late-stage Trial, Shares Plummet
4.
PRO Data Strengthen Case for Dato-DXd in First-Line TNBC
5.
Study looks into cancer-related harmful communication.
1.
Unraveling the Mysteries of Lymphoma: A Journey into the Unknown
2.
Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances
3.
Colorectal Cancer Uncovered: CME, Case Studies, and Clinical Strategies
4.
Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options
5.
Risk Assessment of Cancer-Associated Thrombotic Events
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
4.
Oropharyngeal Cancer in Relation to HPV Status
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation